References
- Adejumo AC, Ajayi TO, Adegbala OM, Bukong TN. 2019. Higher odds of irritable bowel syndrome among hospitalized patients using cannabis: a propensity-matched analysis. Eur J Gastroenterol Hepatol. 31(7):756–765. doi:10.1097/MEG.0000000000001382.
- Adorjan K, Chrobok AI, Koller G, Karch S, Pogarell O. 2020. Epileptic Spikes in EEG and migraine attacks in the course of cannabis withdrawal: A case report. Clin EEG Neurosci. 51(1):45–50. doi:10.1177/1550059419886704.
- Alhouayek M, Muccioli GG. 2017. Chapter 64 - Pharmacological aspects of anandamide and 2-arachidonoyglycerol as bioactive lipids. In: Preedy VR, editor. Handbook of Cannabis and related pathologies [Internet]. San Diego: Academic Press. p. 616–29. [cited 2020 Jan 29]. http://www.sciencedirect.com/science/article/pii/B9780128007563000740.
- Andersson M, Persson M, Kjellgren A. 2017. Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduct J. 14(1):60. doi:10.1186/s12954-017-0186-6.
- Anikwue R, Huffman JW, Martin ZL, Welch SP. 2002. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. J Pharmacol Exp Ther. 303(1):340–346. doi:10.1124/jpet.303.1.340.
- Are You Endocannabinoid Deficient? 2017. [Internet]. CBD School. [cited 2020 Jan 27]. https://www.cbdschool.com/endocannabinoid-deficiency-syndrome/.
- Are You EndoCannabinoid Deficient? 2020. Here’s How to Tell… [Internet]. Emerald Health Bioceuticals. [cited 2020 Jan 20]. https://emeraldhealthbio.com/blogs/news/are-you-endocannabinoid-deficient-here-s-how-to-tell.
- Arigony ALV, de Oliveira IM, Machado M, Bordin DL, Bergter L, Prá D, Henriques JAP. 2013. The influence of micronutrients in cell culture: a reflection on viability and genomic stability. Biomed Res Int. 2013:597282. [cited 2019 Oct 13]). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678455/. doi:10.1155/2013/597282.
- Aviram J, Samuelly-Leichtag G. 2018. Efficacy of Cannabis-based medicines for pain management: A systematic review and meta-analysis of randomized controlled trials. Pain Phys. 1(21;1):E81–96. doi:10.36076/ppj.2018.1.E81.
- Ayers JW, Caputi TL, Leas EC. 2019. The need for federal regulation of marijuana marketing. JAMA. 321(22):2163–2164. doi:10.1001/jama.2019.4432.
- Azcarate PM, Zhang AJ, Keyhani S, et al. 2020. Medical reasons for marijuana use, forms of use, and patient perception of physician attitudes among the US Population. J Gen Intern Med.
- Baram L, Peled E, Berman P, Yellin B, Besser E, Benami M, Louria-Hayon I, Lewitus GM, Meiri D. 2019. The heterogeneity and complexity of Cannabis extracts as antitumor agents. Oncotarget. 10(41):4091–4106. doi:10.18632/oncotarget.26983.
- Barnes MP. 2006. Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother. 7(5):607–615. doi:10.1517/14656566.7.5.607.
- Beckmann YY, Seçkin M, Manavgat Aİ, Zorlu N. 2012. Headaches related to psychoactive substance use. Clin Neurol Neurosurg. 114(7):990–999. doi:10.1016/j.clineuro.2012.02.041.
- Berlin JA, Golub RM. 2014. Meta-analysis as Evidence: Building a better pyramid. JAMA. 312(6):603–606. doi:10.1001/jama.2014.8167.
- Bishay P, Häussler A, Lim H-Y, Oertel B, Galve-Roperh I, Ferreirós N, Tegeder I. 2013. Anandamide deficiency and heightened neuropathic pain in aged mice. Neuropharmacology. 71:204–215. doi:10.1016/j.neuropharm.2013.03.021.
- Bisogno T, De Petrocellis L, Di Marzo V. 2002. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des. 8(7):533–547. doi:10.2174/1381612023395655.
- Boehnke KF, Scott JR, Litinas E, et al. 2019. High frequency medical cannabis use is associated with worse pain among individuals with chronic pain. J Pain.
- Bothwell LE, Greene JA, Podolsky SH, Jones DS. 2016. Assessing the Gold Standard-Lessons from the History of RCTs. N Engl J Med. 374(22):2175–2181. doi:10.1056/NEJMms1604593.
- Burns PB, Rohrich RJ, Chung KC. 2011. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 128(1):305–310. doi:10.1097/PRS.0b013e318219c171.
- Cavazos-Rehg PA, Krauss MJ, Cahn E, Lee KE, Ferguson E, Rajbhandari B, Sowles SJ, Floyd GM, Berg C, Bierut LJ. 2019. Marijuana promotion online: an investigation of dispensary practices. Prev Sci. 20(2):280–290. doi:10.1007/s11121-018-0889-2.
- CBD and Parkinson’s Disease. 2020. [Internet]. [cited 2020 Jan 25]. https://www.projectcbd.org/science/cannabis-pharmacology/cbd-and-parkinsons-disease.
- Chen R, Zhang J, Fan N, Teng Z-Q, Wu Y, Yang H, Tang Y-P, Sun H, Song Y, Chen C, et al. 2013. Δ9-THC-Caused Synaptic and memory impairments are mediated through COX-2 Signaling. Cell. 155(5):1154–1165. doi:10.1016/j.cell.2013.10.042.
- Cogan PS. 2019. On healthcare by popular appeal: critical assessment of benefit and risk in cannabidiol based dietary supplements. Expert Rev Clin Pharmacol. 12(6):501–511. doi:10.1080/17512433.2019.1612743.
- Cogan PS. 2020. The ‘entourage effect’ or ‘hodge-podge hashish’: the questionable rebranding, marketing, and expectations of cannabis polypharmacy. Expert Review of Clinical Pharmacology. 0(0):1–11.
- Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S. 2016. Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. Neurosci Biobehav Rev. 64:359–381. doi:10.1016/j.neubiorev.2016.03.010.
- Colizzi M, Weltens N, McGuire P, et al. 2019. Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. Mol Psychiatry. https://doi.org/10.1038/s41380-019-0374-8
- Commissioner of the A Brief History of the Center for Drug Evaluation and Research. 2019. FDA [Internet]. [cited 2019 Jul 24]). http://www.fda.gov/about-fda/virtual-exhibits-fda-history/brief-history-center-drug-evaluation-and-research.
- Commissioner of the Drug Study Designs. 2019. [Internet]. U.S. Food and Drug Administration. FDA. [cited 2020 Apr 25]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-study-designs.
- Commissioner of the FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). 2020. FDA [Internet]. [cited 2020 Feb 12]). http://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.
- Commissioner of the Public Health Focus. 2018. Warning Letters and Test Results for Cannabidiol-Related Products [Internet]. [cited 2018 Jun 12]. https://www.fda.gov/NewsEvents/PublicHealthFocus/ucm484109.htm.
- Conditions | Project CBD. 2020. [Internet]. [cited 2020 Apr 25]. https://www.projectcbd.org/conditions-hub.
- Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, Fusar-Poli P. 2009. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 24(7):515–523. doi:10.1002/hup.1048.
- Crippa JAS, Hallak JEC, Machado-de-Sousa JP, Queiroz RHC, Bergamaschi M, Chagas MHN, Zuardi AW. 2013. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther. 38(2):162–164. doi:10.1111/jcpt.12018.
- Cupini LM, Costa C, Sarchielli P, Bari M, Battista N, Eusebi P, Calabresi P, Maccarrone M. 2008. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol Dis. 30(2):186–189. doi:10.1016/j.nbd.2008.01.003.
- Cuttler C, Spradlin A, Cleveland MJ, Craft RM. 2019. Short- and long-term effects of cannabis on headache and migraine. J Pain [Internet]. [cited 2020 Feb 4]). http://www.sciencedirect.com/science/article/pii/S152659001930848X. [Mismatch] doi:10.1016/j.jpain.2019.11.001.
- Deng L, Ng L, Ozawa T, Stella N. 2017. Quantitative analyses of synergistic responses between cannabidiol and DNA-damaging agents on the proliferation and viability of glioblastoma and neural progenitor cells in culture. J Pharmacol Exp Ther. 360(1):215–224. doi:10.1124/jpet.116.236968.
- Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 34(5):605–613.
- Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R, et al. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258(5090):1946–1949. doi:10.1126/science.1470919.
- Di Marzo V, De Petrocellis L. 2012. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond, B, Biol Sci. 367(1607):3216–3228. doi:10.1098/rstb.2011.0382.
- DiMasi JA, Grabowski HG, Hansen RW. 2016. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 47:20–33. doi:10.1016/j.jhealeco.2016.01.012.
- Does endocannabinoid deficiency play a role in these common illnesses? 2019. [Internet]. Leafly. [cited 2020 Jan 20]. https://www.leafly.com/news/health/what-is-endocannabinoid-deficiency.
- Dr. Ethan Russo on CBD & Clinical Endocannabinoid Deficiency. 2020. [Internet]. [cited 2020 Jan 21]. https://www.projectcbd.org/article/dr-ethan-russo-cbd-clinical-endocannabinoid-deficiency.
- el-Mallakh RS. 1987. Marijuana and migraine. Headache. 27(8):442–443. doi:10.1111/j.1526-4610.1987.hed2708442.x.
- ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. 2016. Changes in cannabis potency over the last two decades (1995-2014) - Analysis of current data in the United States. Biol Psychiatry. 79(7):613–619. doi:10.1016/j.biopsych.2016.01.004.
- Endocannabinoid Deficiency Syndrome. 2020. | Learn more [Internet]. CBD Oil Review. [cited 2020 Jan 20]. https://cbdoilreview.org/cbd-cannabidiol/cbd-deficiency.
- Frank C, Himmelstein DU, Woolhandler S, Bor DH, Wolfe SM, Heymann O, Zallman L, Lasser KE. 2014. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. Health Aff (Millwood). 33(8):1453–1459. doi:10.1377/hlthaff.2014.0122.
- Gatta L, Piscitelli F, Giordano C, Boccella S, Lichtman A, Maione S, Di Marzo V. 2012. Discovery of Prostamide F2α and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. PLoS One [Internet]. 7(2):e31111. [cited 2020 Jan 28]). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283613/. doi:10.1371/journal.pone.0031111.
- Greco R, Demartini C, Zanaboni AM, Berliocchi L, Piomelli D, Tassorelli C. 2018. Inhibition of monoacylglycerol lipase: Another signalling pathway for potential therapeutic targets in migraine? Cephalalgia. 38(6):1138–1147. doi:10.1177/0333102417727537.
- Grossman J, Mackenzie FJ. 2005. The randomized controlled trial: gold standard, or merely standard? Perspect. Perspect Biol Med. 48(4):516–534. doi:10.1353/pbm.2005.0092.
- Guindon J, Hohmann AG. 2008. A physiological role for endocannabinoid-derived products of cyclooxygenase-2-mediated oxidative metabolism. Br J Pharmacol. 153(7):1341–1343. doi:10.1038/bjp.2008.41.
- Harrison RK. 2016. Phase II and phase III failures: 2013-2015. Nat Rev Drug Discov. 15(12):817–818. doi:10.1038/nrd.2016.184.
- Hart S, Fischer OM, Ullrich A. 2004. Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64(6):1943–1950. doi:10.1158/0008-5472.can-03-3720.
- Häuser W, Petzke F, Fitzcharles MA. 2018. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - An overview of systematic reviews. Eur J Pain. 22(3):455–470. doi:10.1002/ejp.1118.
- Haller JS. 1989. Opium Usage in Nineteenth Century Therapeutics. Bulletin of the New York Academy of Medicine. 65(5):591–607.
- How Cannabis oil works to kill cancer. 2018. [Internet]. www.CureYourOwnCancer.org. [cited 2018 Jul 21]. http://www.cureyourowncancer.org/how-cannabis-oil-works.html.
- Hu SS-J, Bradshaw HB, Chen JS-C, Tan B, Walker JM. 2008. Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. Br J Pharmacol. 153(7):1538–1549. doi:10.1038/bjp.2008.33.
- Human Receptor Information. 2020. [Internet]. Idrasil® RX. [cited 2020 Apr 14]. https://www.idrasilrx.com/human-receptor-information/.
- Ibeas Bih C, Chen T, Nunn AVW, Bazelot M, Dallas M, Whalley BJ. 2015. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 12(4):699–730. doi:10.1007/s13311-015-0377-3.
- Idrasil Launches as First Standardized Form of Prescription Medical Cannabis in a Pill. 2018. [Internet]. AlleyWatch. [cited 2020 Apr 14]. https://www.alleywatch.com/2018/09/idrasil-launches-as-first-standardized-form-of-prescription-medical-cannabis-in-a-pill/.
- Is CBD Toxic to the Liver? 2020. | Project CBD [Internet]. [cited Jan 25]. https://www.projectcbd.org/science/cbd-toxic-liver.
- Ishida JH, Zhang AJ, Steigerwald S, Cohen BE, Vali M, Keyhani S. 2020. Sources of information and beliefs about the health effects of marijuana. J Gen Intern Med. 35(1):153–159. doi:10.1007/s11606-019-05335-6.
- Jakobsen JC, Gluud C. 2013. The necessity of randomized clinical trials. BJMMR. 3(4):1453–1468. doi:10.9734/BJMMR/2013/3208.
- Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. 2004. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The Lancet. 364(9450):2021–2029. doi:10.1016/S0140-6736(04)17514-4.
- Kantae V, Ogino S, Noga M, Harms AC, van Dongen RM, Onderwater GLJ, van den Maagdenberg AMJM, Terwindt GM, van der Stelt M, Ferrari MD, et al. 2017. Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS. J Lipid Res. 58(3):615–624. doi:10.1194/jlr.D070433.
- Kaufmann I, Schelling G, Eisner C, Richter HP, Krauseneck T, Vogeser M, Hauer D, Campolongo P, Chouker A, Beyer A, et al. 2008. Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology. 33(5):676–685. doi:10.1016/j.psyneuen.2008.02.009.
- Kemnic TR, Coleman M. 2019. Vitamin E Deficiency. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. [cited 2019 Oct 3]. http://www.ncbi.nlm.nih.gov/books/NBK519051/.
- Kuszak AJ, Hopp DC, Williamson JS, Betz JM, Sorkin BC. 2016. Approaches by the US National Institutes of Health to support rigorous scientific research on dietary supplements and natural products. Drug Test Anal. 8(3-4):413–417. doi:10.1002/dta.1931.
- Laaris N, Good CH, Lupica CR. 2010. Delta9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus . Neuropharmacology. 59(1–2):121–127. doi:10.1016/j.neuropharm.2010.04.013.
- Leon AC, Davis LL, Kraemer HC. 2011. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 45(5):626–629. doi:10.1016/j.jpsychires.2010.10.008.
- Li C, Zhu Q, He Q, Wang J, Wang F, Zhang H. 2017. Plasma Levels of Cyclooxygenase-2 (COX-2) and Visfatin during different stages and different subtypes of migraine headaches. Med Sci Monit. 23:24–28. doi:10.12659/msm.899269.
- Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V, et al. 2006. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 318(3):1375–1387. doi:10.1124/jpet.106.105247.
- Lindsey N. 2018. Can you treat irritable bowel syndrome with cannabis? [Internet]. High Times. [cited 2020 Feb 28]. https://hightimes.com/health/can-treat-irritable-bowel-syndrome-cannabis/.
- ltd R and M. Legal Marijuana. 2019. - Global Market Outlook (2017-2026) [Internet]. [cited 2019 Oct 16]. https://www.researchandmarkets.com/reports/4827697/legal-marijuana-global-market-outlook-2017.
- Luc MH, Tsang SW, Thrul J, Kennedy RD, Moran MB. 2020. Content analysis of online product descriptions from cannabis retailers in six US states. Int J Drug Policy. 75:102593. doi:10.1016/j.drugpo.2019.10.017.
- Lukhele ST, Motadi LR. 2016. Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. BMC Complement Altern Med. 16(1):335. doi:10.1186/s12906-016-1280-0.
- Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D. 2006. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci. 63(17):2057–2066. doi:10.1007/s00018-006-6156-x.
- Maxfield L, Crane JS. 2019. Vitamin C Deficiency (Scurvy). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. [cited 2019 Oct 3]. http://www.ncbi.nlm.nih.gov/books/NBK493187/.
- McKallip RJ, Nagarkatti M, Nagarkatti PS. 2005. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol. 174(6):3281–3289. doi:10.4049/jimmunol.174.6.3281.
- McPartland JM, Russo EB. 2001. Cannabis and cannabis extracts. J Cannabis Therap. 1(3–4):103–132. doi:10.1300/J175v01n03_08.
- Mechoulam R, Gaoni Y, et al. 1967. Recent advances in the chemistry of Hashish. In: Ashurst PR, Bohlmann F, Farkas L, editors. Fortschritte der Chemie Organischer Naturstoffe/Progress in the Chemistry of Organic Natural Products/Progrès dans la Chimie des Substances Organiques Naturelles. Vienna: Springer. p. 175–213. [Internet]. [cited 2020 Jan 29]. 10.1007/978-3-7091-8164-5_6.
- Medical Marijuana Archives • High Times [Internet]. 2020. High Times. [cited 2020 Apr 25]. https://hightimes.com/health/medical-marijuana/.
- Mücke M, Phillips T, Radbruch L, et al. 2018. Cannabis‐based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews [Internet]. (3) [cited 2020 Mar 10]). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012182.pub2/abstract.
- Munro S, Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365(6441):61–65. doi:10.1038/365061a0.
- No Brainer: CBD & THC for Head Injuries. 2020. [cited 2020 Jan 25]. https://www.projectcbd.org/medicine/no-brainer-cbd-thc-head-injuries.
- Nurmikko TJ, Serpell MG, Hoggart B, et al. 2007. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. PAIN®. 133(1–3):210–220. [AQ]
- Ogunbiyi MO, Hindocha C, Freeman TP, Bloomfield MAP. 2020. Acute and chronic effects of Δ9-tetrahydrocannabinol (THC) on cerebral blood flow: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 101:109900. doi:10.1016/j.pnpbp.2020.109900.
- Ohno-Shosaku T, Kano M. 2014. Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol. 29:1–8. doi:10.1016/j.conb.2014.03.017.
- Parapia LA. 2008. History of bloodletting by phlebotomy. Br J Haematol. 143(4):490–495. doi:10.1111/j.1365-2141.2008.07361.x.
- Pardutz A, Schoenen J. 2010. NSAIDs in the acute treatment of migraine: A review of clinical and experimental data. Pharmaceuticals (Basel). 3(6):1966–1987. doi:10.3390/ph3061966.
- Patel RS, Goyal H, Satodiya R, Tankersley WE. 2020. Relationship of cannabis use disorder and Irritable Bowel Syndrome (IBS): An analysis of 6.8 million hospitalizations in the United States. Subst Use Misuse. 55(2):281–290. doi:10.1080/10826084.2019.1664591.
- Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS. 2007. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 334(7586):197. doi:10.1136/bmj.39048.407928.BE.
- Pergam SA, Woodfield MC, Lee CM, Cheng G-S, Baker KK, Marquis SR, Fann JR. 2017. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer. 123(22):4488–4497. doi:10.1002/cncr.30879.
- Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, et al. 2010. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacol Rev. 62(4):588–631. doi:10.1124/pr.110.003004.
- Prescribing Idrasil®. 2020. [Internet]. Idrasil® RX. [cited 2020 Jan 20]. https://www.idrasilrx.com/prescribing-idrasil/.
- Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, Wichers R, Ajram L, Ivin G, Heasman M, et al. 2019. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology. 44(8):1398–1405. doi:10.1038/s41386-019-0333-8.
- Ramer R, Merkord J, Rohde H, Hinz B. 2010. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol. 79(7):955–966. doi:10.1016/j.bcp.2009.11.007.
- Russo E. 2015. Endocannabinoid Deficiency| Ganjapreneur [Internet]. Ganjapreneur.com. [cited 2020 Jan 21]. https://www.ganjapreneur.com/ethan-russo-endocannabinoid-deficiency-medical-cannabis/.
- Russo E. 2001. Cannabinoids in pain management. BMJ. 323(7323):1249.
- Russo EB. 2008. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 29(2):192–200.
- Russo EB. 2011. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344–1364. doi:10.1111/j.1476-5381.2011.01238.x.
- Russo EB. 2016. Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res. 1(1):154–165. doi:10.1089/can.2016.0009.
- Russo EB. 2018. The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No “Strain. No Gain. Front Plant Sci. 9:1969.
- Salottolo K, Peck L, Tanner Ii A, Carrick MM, Madayag R, McGuire E, Bar-Or D. 2018. The grass is not always greener: a multi-institutional pilot study of marijuana use and acute pain management following traumatic injury. Patient Saf Surg. 12(1):16. doi:10.1186/s13037-018-0163-3.
- Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, Calabresi P. 2007. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacol. 32(6):1384–1390. doi:10.1038/sj.npp.1301246.
- Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, Wright S, White L, Duncombe P, Chen C-F, et al. 2013. A multiple-dose, randomized, double-blind, placebo-controlled, parallel-group QT/QTc study to evaluate the electrophysiologic effects of THC/CBD Spray. Clin Pharmacol Drug Dev. 2(3):285–294. doi:10.1002/cpdd.36.
- Shi S, Brant AR, Sabolch A, et al. 2019. False news of a cannabis cancer cure. Cureus [Internet]. 11(1). [cited 2019 Oct 8]). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426557/.
- Sink R, Gobec S, Pečar S, Zega A. 2010. False positives in the early stages of drug discovery. Curr Med Chem. 17(34):4231–4255. doi:10.2174/092986710793348545.
- Skelley JW, Deas CM, Curren Z, Ennis J. 2020. Use of cannabidiol in anxiety and anxiety-related disorders. J Am Pharm Assoc (2003). 60(1):253–261. doi:10.1016/j.japh.2019.11.008.
- Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. 2017. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction. 112(12):2167–2177. doi:10.1111/add.13886.
- Smith SC, Wagner MS. 2014. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 35(3):198–201.
- Solowij N, Broyd S, Greenwood L-m, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, et al. 2019. A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci. 269(1):17–35. [cited 2019 Jan 28]). doi:10.1007/s00406-019-00978-2.
- Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. 2017. Cannabinoid hyperemesis syndrome: Diagnosis, pathophysiology, and treatment-a systematic review. J Med Toxicol. 13(1):71–87. doi:10.1007/s13181-016-0595-z.
- Staff R. 2020. Buy CBD Oils: 250mg, 500mg, 1000mg, & 2500mg (Full Spectrum) [Internet]. https://royalcbd.com/. [cited 2020 Mar 10]. https://royalcbd.com/cbd-oils/.
- Stensson N, Ghafouri N, Ernberg M, Mannerkorpi K, Kosek E, Gerdle B, Ghafouri B. 2018. The relationship of endocannabinoidome lipid mediators with pain and psychological stress in women with fibromyalgia: A Case-Control Study. J Pain. 19(11):1318–1328. doi:10.1016/j.jpain.2018.05.008.
- Structure of Cannabinol. 2020. III. Synthesis of Cannabinol, 1-Hydroxy-3-n-amyl-6,6,9-trimethyl-6-dibenzopyran1 [Internet]. [cited Jan 29]. https://pubs.acs.org/doi/pdf/10.1021/ja01865a083.
- Stuyt E. 2018. The problem with the current high potency THC marijuana from the perspective of an addiction psychiatrist. Mo Med. 115(6):482–486.
- Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K. 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 215(1):89–97. doi:10.1006/bbrc.1995.2437.
- Suh Y-G, Oh U. 2005. Activation and activators of TRPV1 and their pharmaceutical implication. Curr Pharm Des. 11(21):2687–2698. doi:10.2174/1381612054546789.
- Tassorelli C, Greco R, Armentero MT, et al. 2020. A role for brain Cyclooxygenase‐2 and Prostaglandin‐E2 in Migraine: Effects of Nitroglycerin. International Review of Neurobiology [Internet]. Academic Press; p. 373–822007 [cited 2020 Jan 30]. http://www.sciencedirect.com/science/article/pii/S0074774207820204.
- Team HBT. 2018. Why CECD Is the Hidden Scourge of Healthcare [Internet]. Healthcare Business Today. [cited 2020 Jan 20]. https://www.healthcarebusinesstoday.com/why-cecd-is-the-hidden-scourge-of-healthcare/.
- The Antioxidant Properties of CBD. 2020. - RQS Blog [Internet]. [cited 2020 Mar 10]. https://www.royalqueenseeds.com/blog-the-antioxidant-properties-of-cbd-n1061.
- The Endocannabinoid System | Learn More. 2020. [Internet]. CBD Oil Review. [cited 2020 Mar 15]. https://cbdoilreview.org/cbd-cannabidiol/endocannabinoid-system.
- Ujváry I, Hanuš L. 2016. Human metabolites of cannabidiol: A review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 1(1):90–101. doi:10.1089/can.2015.0012.
- Walter C, Oertel BG, Lötsch J. 2015. THC may reproducibly induce electrical hyperalgesia in healthy volunteers. Eur J Pain. 19(4):516–518. doi:10.1002/ejp.575.
- Zhang J, Chen C. 2008. Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem. 283(33):22601–22611. doi:10.1074/jbc.M800524200.
- Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, Dubinett SM. 2000. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. 165(1):373–380. doi:10.4049/jimmunol.165.1.373.